Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/30465
Full metadata record
DC FieldValueLanguage
dc.contributor.authorButi, María
dc.contributor.authorManzano, María L
dc.contributor.authorMorillas, Rosa M
dc.contributor.authorGarcía-Retortillo, Montserrat
dc.contributor.authorMartín, Leticia
dc.contributor.authorPrieto, Martín
dc.contributor.authorGutiérrez, María L
dc.contributor.authorSuárez, Emilio
dc.contributor.authorGómez Rubio, Mariano
dc.contributor.authorLópez, Javier
dc.contributor.authorCastillo, Pilar
dc.contributor.authorRodríguez, Manuel
dc.contributor.authorZozaya, José M
dc.contributor.authorSimón, Miguel A
dc.contributor.authorMorano, Luis E
dc.contributor.authorCalleja, José L
dc.contributor.authorYébenes, María
dc.contributor.authorEsteban, Rafael
dc.date.accessioned2019-06-28T16:16:03Z-
dc.date.available2019-06-28T16:16:03Z-
dc.date.issued2017
dc.identifier.citationPLoS ONE.2017;(12)9:e0184550
dc.identifier.urihttps://hdl.handle.net/20.500.12530/30465-
dc.description.abstractHepatitis B virus (HBV) reactivation in patients with resolved HBV infection (HBsAg negative, antiHBc positive) is uncommon, but potentially fatal. The role of HBV prophylaxis in this setting is uncertain. The aim of this study was to compare the efficacy of tenofovir disoproxil fumarate (TDF) prophylaxis versus close monitoring in antiHBc-positive, HBsAg-negative patients under treatment with rituximab (RTX)-based regimens for hematologic malignancy.
dc.language.isoeng
dc.rightsopenAccess-
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntineoplastic Agents
dc.subject.meshAntiviral Agents
dc.subject.meshFemale
dc.subject.meshHepatitis B
dc.subject.meshHepatitis B virus
dc.subject.meshHumans
dc.subject.meshLeukemia
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPost-Exposure Prophylaxis
dc.subject.meshRituximab
dc.subject.meshSerologic Tests
dc.subject.meshTenofovir
dc.titleRandomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study.
dc.typeArtículo
dc.identifier.pubmedID28898281
dc.format.volume12
dc.format.pagee0184550
dc.identifier.e-issn1932-6203
dc.identifier.journalPloS one
dc.identifier.doi10.1371/journal.pone.0184550
dc.format.number9
dc.identifier.pmcPMC5595327
dc.pubmedtypeClinical Trial, Phase IV
dc.pubmedtypeJournal Article
dc.pubmedtypeMulticenter Study
dc.pubmedtypeRandomized Controlled Trial
Appears in Collections:Hospitales > H. U. Fundación Alcorcón > Artículos
Hospitales > H. U. 12 de Octubre > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. Getafe > Artículos
Hospitales > H. U. Puerta de Hierro Majadahonda > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. 12 de Octubre > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. La Paz > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. Puerta de Hierro-Segovia de Arana > Artículos

Files in This Item:
File Description SizeFormat 
PMC5595327.pdf1.66 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.